IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.688
EU - Europa 5.378
AS - Asia 2.755
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 12
AF - Africa 10
OC - Oceania 4
Totale 14.864
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.671
CN - Cina 1.095
IE - Irlanda 1.016
UA - Ucraina 900
SG - Singapore 788
SE - Svezia 761
IT - Italia 708
FR - Francia 675
TR - Turchia 609
GB - Regno Unito 552
DE - Germania 328
IN - India 167
FI - Finlandia 144
RU - Federazione Russa 138
VN - Vietnam 69
BE - Belgio 46
AT - Austria 29
CZ - Repubblica Ceca 29
EU - Europa 17
CA - Canada 14
PL - Polonia 10
IL - Israele 6
BR - Brasile 5
EG - Egitto 5
ID - Indonesia 5
NL - Olanda 5
AU - Australia 4
CH - Svizzera 4
DK - Danimarca 4
ES - Italia 4
GR - Grecia 4
HK - Hong Kong 4
LT - Lituania 4
RO - Romania 4
CL - Cile 3
HR - Croazia 3
JP - Giappone 3
TW - Taiwan 3
BG - Bulgaria 2
IR - Iran 2
MA - Marocco 2
MX - Messico 2
PY - Paraguay 2
AM - Armenia 1
BO - Bolivia 1
BS - Bahamas 1
DZ - Algeria 1
EE - Estonia 1
HU - Ungheria 1
LU - Lussemburgo 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 14.864
Salva come PNG Salva come JPEG
Città #
Chandler 1.478
Jacksonville 1.167
Dublin 1.007
Singapore 674
Princeton 466
Southend 414
Izmir 376
Nanjing 341
Ashburn 270
Wilmington 224
Beijing 205
Dearborn 189
Ann Arbor 177
Cambridge 174
Altamura 167
Boardman 148
Santa Clara 148
Chieti 138
Nanchang 125
Woodbridge 93
Houston 80
New York 77
Los Angeles 72
Dong Ket 68
Shenyang 62
Hebei 60
Kunming 52
Tianjin 49
Brussels 46
Washington 43
Jiaxing 40
Norwalk 37
Vienna 29
Munich 27
Rome 26
Brno 22
Falls Church 22
Changsha 21
Hangzhou 20
Helsinki 20
Seattle 20
Kocaeli 19
San Mateo 17
Lanzhou 16
Pescara 15
Auburn Hills 14
Tappahannock 14
Changchun 13
Grevenbroich 12
Milan 12
Augusta 11
Chicago 11
Guangzhou 11
Ningbo 11
Düsseldorf 10
Edinburgh 10
Frontone 10
London 10
Jinan 9
Leawood 9
Fairfield 8
Giaveno 8
Moscow 8
Aprilia 7
Hefei 7
Shanghai 7
Zhengzhou 7
Collecorvino 6
Giulianova 6
Menlo Park 6
Orange 6
Romola 6
Bristol 5
Cairo 5
Monmouth Junction 5
Mumbai 5
Ottawa 5
Pune 5
Redwood City 5
Anzio 4
Denver 4
Napoli 4
Olomouc 4
Paris 4
Shaoxing 4
Spoltore 4
Toronto 4
Altino 3
Ameno 3
Amsterdam 3
Avellino 3
Clifton 3
Copenhagen 3
Francavilla al Mare 3
Haikou 3
Hanover 3
Jinhua 3
Keputih 3
Leicester 3
Madrid 3
Totale 9.296
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 123
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 116
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 115
A multidisciplinary group for prostate cancer management: A single institution experience 112
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 108
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 107
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 103
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 100
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 98
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 98
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 97
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 97
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 97
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 97
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 96
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 96
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 93
Surgical treatment of adrenal metastases from non small cell lung cancer 93
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 92
DNA ploidy and S-phase fraction in pulmonary carcinoids. 91
90K (Mac-2 BP) in human milk 90
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 90
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 90
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 89
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 89
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 88
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 88
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 87
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 86
Chemotherapy preoperative for the management of breast cancer locally advanced 86
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 86
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 86
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 86
Principali effetti collaterali delle terapie mediche 86
Tyrosine kinase inhibitors 86
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 86
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 86
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 85
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 85
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 85
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 85
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 85
Unknown primary tumors 84
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 84
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 84
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 84
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 83
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 83
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 82
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 82
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 81
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 81
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 81
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 80
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 80
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 80
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 80
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 80
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 80
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 79
New Targets for Therapy in Pancreatic Cancer 79
Tumor-derived microvesicles: The metastasomes. 79
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 79
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 79
Prognostic value of 90K protein in HIV infection 78
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 78
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 78
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 78
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 78
Interleukin-30 Promotes Breast Cancer Growth and Progression 78
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 78
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 78
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 77
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies 77
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 77
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 77
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 76
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 76
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 76
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 75
Prognostic value of a novel circulating serum 90K antigen in breast cancer 75
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 75
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 75
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 74
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 74
Rivaroxaban for cancer-associated cardiac thrombosis 74
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 74
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 73
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 73
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 73
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 73
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 73
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 73
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis 73
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 72
Combinations of biological response modifiers: rationale and clinical responses. 72
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. 72
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 72
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 72
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 72
Totale 8.422
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.872 0 0 0 108 248 203 307 223 168 268 322 25
2020/20211.456 228 22 278 12 90 287 34 43 97 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20251.475 202 692 532 49 0 0 0 0 0 0 0 0
Totale 15.706